Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
Frequently asked questions
What sector does Calliditas Therapeutics (CALTX) operate in?
Calliditas Therapeutics belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Calliditas Therapeutics (CALTX) current stock price?
As of the latest data, Calliditas Therapeutics stock price is SEK 208.00, with a previous close of SEK 208.00.
What is Calliditas Therapeutics (CALTX) current market capitalization?
Calliditas Therapeutics market cap is approximately 11.24 billion.
What is Calliditas Therapeutics (CALTX) Earnings Per Share (EPS)?
The trailing EPS is -SEK 8.95, and the forward EPS is SEK 13.45.
Does Calliditas Therapeutics (CALTX) pay dividends?
No. Calliditas Therapeutics does not pay a dividend.
What is Calliditas Therapeutics (CALTX) beta (volatility) score?
Calliditas Therapeutics has a beta of 1.457, suggesting it is more volatile than the market.
